Roth Capital lowered the firm's price target on LanzaTech to $14 from $20 and keeps a Neutral rating on the shares after its Q3 results, with revenue coming in light of estimates. The firm remains cautious on the stock due to the company's near-term funding challenges, its inability to execute on financial targets, and its capital structure, which contemplates "very dilutive future funding", the analyst tells investors in a research note.
